To use advanced imaging technologies of atherosclerosis in the coronary and carotid arteries together with information obtained by proteomics/metabolomics/genomics technologies to improve risk prediction for cardiovascular disease. The clinical implications would be better-targeted intensive risk factor interventions, which will save both lives and medical costs.
To improve the understanding of underlying mechanisms of disease in cardiovascular disease and chronic obstructive pulmonary disease. An example is the use of detailed metabolic imaging with computed tomography (CT) to elucidate the links between fat deposition patterns and risk of subclinical atherosclerosis and the development of cardiovascular disease in persons with and without chronic obstructive pulmonary disease. This could lead to the discovery of new treatment targets and preventive strategies.
To improve the understanding of the epidemiology of cardiovascular disease and chronic obstructive pulmonary disease. An example is investigating why high morbidity and mortality rates from cardiovascular disease and chronic obstructive pulmonary disease persist in individuals with low socioeconomic status, despite an overall reduction in mortality from cardiovascular disease and a levelling of age-adjusted mortality for chronic obstructive pulmonary disease. This could lead to improved care of chronic obstructive pulmonary disease patients to prevent cardiovascular disease, and better-targeted intervention in persons with a low socioeconomic status.
To evaluate the cost-effectiveness of using new imaging techniques and modern -omics technologies to target preventive efforts against cardiovascular disease and chronic obstructive pulmonary disease.
SCAPIS is made possible through a collaborative effort between the following six Swedish universities and university hospitals. The main funder of SCAPIS is the Swedish Heart-Lung Foundation.
